Product ID: SQMIG35I2155
Report ID:
SQMIG35I2155 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
60 |
Figures:
75
In March 2024, Croda International entered a collaboration agreement with the Access to Advanced Health Institute (AAHI) to innovate and develop vaccine adjuvant formulations.
In February 2024, the United States’ Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks Inc. and SaponiQx, Inc. (a subsidiary of Agenus Inc.) to discover and develop next-generation vaccine adjuvants.
In November 2023, Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35I2155